<DOC>
	<DOCNO>NCT00740155</DOCNO>
	<brief_summary>This part ongoing effort develop satisfactory dengue vaccine : Primary objective : To describe safety vaccination bivalent tetravalent formulation dengue vaccine candidate . To describe immune response vaccination dengue vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Formulations Dengue Vaccines Healthy Flavivirus-Na√Øve Adults</brief_title>
	<detailed_description>Subjects randomize five group receive assign vaccine follow 12 month .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Healthy determine medical history , clinical examination , biological safety parameter Aged 18 45 year day inclusion . Informed consent form sign . Able attend schedule visit comply trial procedure For woman childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination . Exclusion Criteria : History thymic disease thymectomy . For woman childbearing potential , know suspected pregnancy positive pregnancy test Breastfeeding Current abuse alcohol drug addiction may interfere subject 's ability comply trial procedure . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent . Human Immunodeficiency Virus ( HIV ) , Hepatitis B ( HBs Ag ) Hepatitis C ( HC ) seropositivity blood sample take screening . Laboratory abnormality consider clinically significant upon Investigator 's judgment intensity threshold ( define protocol ) blood sample take screening . Participation another clinical trial 4 week precede first trial vaccination . Planned participation another clinical trial present trial period . Previous residence travel 2 week area high dengue infection endemicity . Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance ( i.e . egg , egg product , protein rodent neural origin , gelatin , thimerosal . History urticaria hymenoptera envenomation . History flavivirus infection report subject . Previous vaccination flavivirus disease ( include Japanese encephalitis , tickborne encephalitis , yellow fever ) . Planned travel present trial period area high dengue infection endemicity . Congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm ( least 2 week within previous 3 month ) systemic corticosteroid therapy ( dose least 10 mg ) . Chronic illness stage could interfere trial conduct completion . Blood bloodderived product receive past 3 month . Any vaccination 4 week precede first trial vaccination . Vaccination plan 4 week follow trial vaccination . Flavivirus vaccination plan present trial period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Dengue virus</keyword>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>Dengue disease</keyword>
</DOC>